Reminder: July 15 Deadline for Abstracts on Injection Drug Use

Content From: Jonathan Mermin, M.D., M.P.H., RADM and Assistant Surgeon General, USPHS, Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and PreventionPublished: July 05, 20192 min read



The Journal of Infectious Diseases (JID) and the US Centers for Disease Control (CDC) are inviting submissions for a thematic supplement on injection drug use (IDU): "Infectious Diseases and Injection Drug Use: Public Health Burden and ResponseExit Disclaimer." This supplement includes guest editors from the Centers for Disease Control and Prevention's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

As a first step, authors are asked to submit abstractsExit Disclaimer no later than midnight on July 15, 2019. Based on review of the abstracts, some authors will be invited to submit full manuscripts for peer review.

Submissions should be scholarly in nature and contribute new scientific knowledge or public health practice. This supplement is intended to present timely articles on disease epidemiology as well as policy, programmatic, and scientific interventions or strategies that have affected the burden, outcomes, or disparities of IDU-associated infections. An illustrative (not exclusive) list of example topics would include the following:

  • Reducing infections associated with injection drug use.
  • Integrating treatment for IDU-associated infections with treatment for drug use disorders.
  • Improving collection and analysis of data on drug use, drug-related behaviors, and IDU-associated infections to optimize and target interventions.
  • Identifying emerging issues associated with IDU.
  • Sharing lessons learned from large outbreaks associated with drug use.

Again, abstract submissions are due to JID no later than midnight on July 15, 2019. Detailed informationExit Disclaimer about manuscript topics, formatting, and submission requirements is available online.